Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2021

View Archived Issues

A different path to specificity for Ras inhibitors

Crinetics opens phase III study of paltusotine to treat acromegaly

LIB Therapeutics initiates phase III studies of lerodalcibep in hypercholesterolemia

BioNTech and Regeneron evaluate the combination of BNT-111 and cemiplimab in melanoma

Anti-CD6 therapy suppresses autoimmunity and enhances cancer cell death

Characterization of HSK-16149, a selective ligand of VGCC alpha2delta subunit

Phase I trial of a vaccine targeting tumor-associated antigens PSA, MUC-1 and brachyury in mCRPC

Adrenaline release immobilizes immune cell responses

Gene variants linked to premenstrual dysphoric disorder

IL-12 immunoconjugate SON-1010 generally well tolerated in cynomolgus monkeys

FDA clears IND application for PF-614-MPAR opioid with overdose protection

Patient dosing begins in phase Ib/II study of CFI-400945 in leukemia

European Commission approves Orladeyo for the prevention of HAE attacks

New model of metabolic syndrome-induced CKD in mice

Janssen Pharmaceutica divulges CB1 and/or CB2 receptor agonists

Esteve Pharmaceuticals patents new analgesics

Monte Rosa Therapeutics discloses new protein cereblon modulators

Heptares Therapeutics presents EP4 receptor antagonists

U.S. researchers discover new CARs against cytomegalovirus

FDA approves Farxiga for chronic kidney disease

FDA approves Ferriprox to treat transfusional iron overload due to sickle cell disease

Researchers identify new markers of treatment response in alcohol use disorder

FDA issues complete response letter for tralokinumab in moderate to severe atopic dermatitis

Synairgen reports home cohort and combined analysis from phase II trial of SNG-001 in COVID-19

Repare initiates phase I trial of oral PKMYT1 inhibitor RP-6306

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...